Global pharma major Lupin Limited announced the US launch of tavaborole topical solution, 5% having received an approval from the United States Food and Drug Administration (FDA). The product will be manufactured at Lupin’s facility in Pithampur, India.

Tavaborole topical solution, 5%, is generic equivalent of Kerydin topical solution, 5%, of Anacor Pharmaceuticals, Inc. and is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails due to trichophyton rubrum or trichophyton mentagrophytes.

Tavaborole topical solution, 5% has an estimated annual sales of US$ 53 million in the US, according to IQVIA MAT May 2021.